Here we validate this strategy by considering a real case by implementing a strategy that could eventually represent an innovative therapeutic approach to treat the GAMT deficiency, a rare neurometabolic disease with a severe clinical outcome. Here, GAMT is linked to hyperinsulinemic hypoglycemia, familial, 4.